SCT800 + daratumumab

SCT800 is a recombinant human B-domain-deleted coagulation factor VIII (BDDrFVIII) developed in China for the prophylaxis and treatment of bleeding episodes in patients with severe haemophilia A. It functions as a replacement therapy to restore deficient or absent clotting factor VIII, thereby reducing bleeding risk[6][8]. Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on multiple myeloma cells. By binding to CD38, daratumumab induces apoptosis of these cells through direct cytotoxicity and by recruiting immune effector mechanisms such as macrophages, natural killer cells, and complement proteins. It is approved for use alone or in combination with other drugs for the treatment of multiple myeloma and light chain amyloidosis[2][3][5]. The combination "SCT800 + daratumumab" refers to co-administration of these two agents; however, there is no evidence from the provided sources that this specific combination has been clinically studied or approved as a fixed regimen.

Brand names

DarzalexDarzalex Faspro

Other names

B-domain-deleted recombinant factor VIII (for SCT800)BDDrFVIII (for SCT800)